Clinical trial
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants…
NCT04242498 · UCB Biopharma SRL, Industry · Completed
Key facts
| NCT number | NCT04242498 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| Acronym | BE HEARD II |
| Lead sponsor | UCB Biopharma SRL, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hidradenitis Suppurativa |
| Intervention type | Drug, Other |
| Interventions | Bimekizumab, Placebo |
| Enrollment | 509 |
| Start date | Mar 2, 2020 |
| Primary completion | Nov 9, 2021 |
| Completion | Sep 28, 2022 |
| First posted | Jan 27, 2020 |
| Last update posted | Nov 6, 2025 |
| Countries | Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Ireland, Israel, Japan, Poland, Spain and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: